Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 4891 results
MabVax Therapeutics nominates HuMab 5B1 as lead clinical development candidate
MabVax Therapeutics Holdings, a clinical stage oncology drug development company, has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer.
Drug Research > Drug Discovery & Development > News
Immunotech completes negotiations with Uldic to market potential Ebola treatment in Africa
By PBR Staff Writer
Immunotech Laboratories has completed negotiations with Zimbabwe-based Uldic Investment (Uldic) to pursue the development of market opportunities related to potential treatment of the deadly Ebola virus in Sub-Saharan West Africa.
Drug Research > Drug Discovery & Development > News
Apricus expands development pipeline with in-licensing of US rights for fispemifene
Apricus Biosciences has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator ("SERM"), fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland.
Drug Research > Drug Discovery & Development > News
EYLEA injection shows better gains in visual acuity than both bevacizumab and ranibizumab in NIH-sponsored DME study
Regeneron Pharmaceuticals, has announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA (aflibercept) Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to both bevacizumab (Avastin/Genentech) and ranibizumab injection (Lucentis/Genentech), the primary endpoint of the study.
Drug Research > Drug Discovery & Development > News
GSK update on current development status of the GSK/NIH Ebola vaccine candidate
With the Ebola crisis in West Africa continuing, GSK is working closely with the World Health Organization (WHO), regulators and other partners to respond to the outbreak, to accelerate development of our investigational Ebola vaccine and to ramp up production as quickly as possible.
Drug Research > Drug Discovery & Development > News
FDA approves abuse deterrent labeling for Pfizer's Embeda
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved an updated label for Pfizer's Embeda (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies.
Drug Research > Drug Discovery & Development > News
NeuroSigma, US Veterans Administration (VA) enter into cooperative research and development agreement
NeuroSigma a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs (VA) for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.
Drug Research > Drug Discovery & Development > News
Bristol-Myers, Pharmacyclics and Janssen collaborate for new non-hodgkin lymphoma drug
By PBR Staff Writer
Bristol-Myers Squibb (BMS), Pharmacyclics and Janssen Research & Development have entered into collaboration to conduct a Phase I/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination of Opdivo and Imbruvica in patients with non-Hodgkin lymphoma (NHL).
Drug Research > Drug Discovery & Development > News
HemoShear completes initial development phase of new cancer drug discovery platform
By PBR Staff Writer
HemoShear has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.
Drug Research > Drug Discovery & Development > News
Pharmaceutical firms to use UC San Diego-led resource to share data for drug design
By PBR Staff Writer
Pharmaceutical companies will collaborate with researchers at the University of California, San Diego to provide previously unreleased proprietary data for drug discovery through a new $3.7m effort funded by the National Institutes for Health.
Drug Research > Drug Discovery & Development > News
Blaze Bioscience gets SBIR phase II funding for clinical trial of tumor paint BLZ-100 in sarcoma
Blaze Bioscience, a biotechnology company focused on guided cancer therapy, has been awarded a $1.5m Small Business Innovation Research (SBIR) Phase II contract from the National Cancer Institute (NCI) to study Tumor Paint BLZ-100 in patients with soft tissue sarcoma.
Drug Research > Drug Discovery & Development > News
EMD Serono, ICR, Wellcome Trust collaborate to develop anti-cancer drugs
By PBR Staff Writer
Merck subsidiary EMD Serono, the Institute of Cancer Research (ICR) and the Wellcome Trust have entered into a co-development and license agreement for developing new drug candidates to treat different forms of cancer.
Drug Research > Drug Discovery & Development > News
DiscoveryBioMed awarded Dual SBIR awards for PKD drug discovery and validation
DiscoveryBioMed learned in recent months that it was awarded a new Phase 1 SBIR grant from the National Institutes of Health (NIH) to perform high-throughput screening (HTS)-based drug discovery and validation to discover novel small molecules that attack the secondary phase of autosomal dominant polycystic kidney disease (ADPKD).
Drug Research > Drug Discovery & Development > News
FeF Chemicals - Insulin Human and Benzalkonium Chloride Products
FeF Chemicals is a Novo Nordisk company that specialises in the supply of ingredients for the biopharmaceutical and pharmaceutical industries, such as insulin human for cell culture media and cGMP manufactured quaternary ammonium compounds (usually referred to as quats) such as benzalkonium chloride, cetrimide and cetrimonium bromide.
Drug Research > Drug Discovery & Development > Suppliers
BrainStorm reports last patient visit in Phase IIa ALS trial
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, has announced that the last patient has completed the last visit in its phase 2a clinical trial of NurOwn in Amyotrophic Lateral Sclerosis (ALS), conducted at the Hadassah Medical Center in Jerusalem.
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

FeF Chemicals - Insulin Human and Benzalkonium Chloride Products
FeF Chemicals is a Novo Nordisk company that specialises in the supply of ingredients for the biopharmaceutical and pharmaceutical industries, such as insulin human for cell culture media and cGMP manufactured quaternary ammonium compounds (usually referred to as quats) such as benzalkonium chloride, cetrimide and cetrimonium bromide.... Drug Research > Drug Discovery & Development > Suppliers
Polipharma Industries - Pharmaceutical Product Manufacturer
Polipharma Industries is a GMP-certified drug manufacturer established in 2003, whose core business is the manufacturing of pharmaceutical products. We provide activities and services such as: research & development, out-licensing, contract manufacturing, contract development, batch release, analytical services and clinical trials.... Drug Research > Drug Discovery & Development > Suppliers
Alpex Pharma - High Quality Formulation Development & Manufacturing Company
Alpex Pharma is a pharmaceutical company active in Research & Development and Production of ODT (Orally Dispersible Tablet) called also "fast melt" and effervescent tablets. Alpex Pharma has developed a unique proprietary covering ODT technology.... Drug Research > Drug Discovery & Development > Suppliers
NNIT - Full-Service IT Consultancy
With 15 years’ experience, NNIT understands the challenges businesses in the life sciences industry are facing. And we have the solutions.... Drug Research > Drug Discovery & Development > Suppliers
PolyPeptide Group - Proprietary and Generic GMP-Grade Peptides
The PolyPeptide Group is a privately-held group of manufacturing companies that focuses on proprietary and generic GMP-grade peptides for the pharmaceutical, cosmetic and biotechnological market.... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

Why You Should be Using Ultrasonic Cleaning By Natoli Engineering Company
Clean punches and dies are essential to maintaining the integrity and efficiency of your tooling investment, as well as the quality of your product. Ultrasonic cleaning has long been considered the most effective, nondestructive way to clean tools – from medical instruments to tablet tooling.... Drug Research > Drug Discovery & Development > White Papers Choose the Right Tooling By Natoli Engineering Company
Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.... Drug Research > Drug Discovery & Development > White Papers Eight Ways to Reduce Manufacturing Costs By Natoli Engineering Company
It’s no surprise that in today’s economy, companies are facing budget cuts across the board. In an effort to help our customers address these challenges, we put together this list of eight ways to reduce tablet manufacturing costs.... Drug Research > Drug Discovery & Development > White Papers Seven Inspections Points of Tablet Quality By Natoli Engineering Company
Inspecting tooling and press components for wear or defects could be the most important step in improving tablet quality. There are certain inspection points that are easy to overlook yet can cause significant tablet quality issues and limit tool life. Spend a little time checking the following items for wear or defects to quickly increase tablet quality and reduce tooling cost.... Drug Research > Drug Discovery & Development > White Papers IDT Biologika - Pharmaceuticals By IDT Biologika
In the highly specialized world of sterile liquid dosage forms, IDT Biologika is a contract manufacturing organization with the experience, the capability and the commitment to excellence to offer you a strategic advantage in your commercialization process. Our expertise drives our activities into higher-value pharmaceutical and biotechnology applications.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 4891 results